Publication:
6-[(1,4-Naphthoquinone-2-yl)methyl]thio-Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer

Placeholder

Departments

School / College / Institute

Program

KU-Authors

KU Authors

Co-Authors

Busenbender, Tobias
Pelageev, Dmitry N.
Hauschild, Jessica
Kaune, Moritz
Boeckelmann, Lukas
Krisp, Christoph
Elsesy, Mohamed E.
Zielinski, Alexandra
Mair, Thomas
Riedner, Maria

Publication Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

The Warburg effect is a shift from oxidative phosphorylation to anaerobic glycolysis, accompanied by an enormous increase in glucose uptake into cancer cells. We have utilized this effect to design a new group of targeted 1,4-naphthoquinone-glucose derivatives conjugated with a novel thiomethylene linker that are cytotoxic to prostate cancer cells. Compound PeS-9 revealed the highest efficacy and selectivity, which was conditioned by a GLUT-1-mediated uptake. PeS-9 induced androgen receptor degradation followed by downregulation of its signaling. In addition, it increased reactive oxygen species production and induced DNA double-strand breaks. Combinational therapy with PARP inhibitor olaparib resulted in synergistic effects in homologous recombination-deficient cells. The underlying mode of PeS-9's cytotoxic action involved mitochondrial targeting, leading to a loss of mitochondrial membrane potential, release of cytochrome C and apoptosis-inducing factor, activation of caspases-3 and -9, PARP cleavage, and apoptotic cell death. This process was stipulated by downregulation of several antiapoptotic factors and induction of endoplasmic reticulum stress. Moreover, drug-induced activation of signaling pathway mediated by p38, JNK1/2, and ERK1/2 kinases was identified as an important factor of the cytotoxic activity. The anticancer activity of PeS-9 could be confirmed ex vivo using patient-derived tumoroids as well as in vivo in xenografts, demonstrating suppression of tumor growth and decreased dissemination of prostate cancer cells to the lungs. No serious side effects were observed in animal models. This unique combination of anticancer properties makes PeS-9 an attractive candidate for targeted monotherapy against GLUT-1-overexpressing tumors and as a potential combination partner, especially with PARP inhibitors.

Source

Publisher

AMER ASSOC CANCER RESEARCH

Subject

Oncology

Citation

Has Part

Source

MOLECULAR CANCER THERAPEUTICS

Book Series Title

Edition

DOI

10.1158/1535-7163.MCT-24-0955

item.page.datauri

Link

Rights

CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Copyrights Note

Creative Commons license

Except where otherwised noted, this item's license is described as CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details